How Much Does Losartan Cost in Idaho in 2026?

Idaho Cash-Pay Prices for Generic Losartan

Generic losartan is one of the least expensive antihypertensives on the American market. At Idaho retail pharmacies in 2026, a 30-day supply of losartan 50 mg tablets typically costs about $10 without any insurance. Some big-box pharmacies price it even lower through their own discount formularies.

Walmart, Costco, and Fred Meyer locations across Idaho frequently include losartan on $4-per-month generic lists. A 90-day supply often runs between $10 and $12 at these retailers, which means a patient paying entirely out of pocket could spend less than $50 per year on blood pressure control. The FDA-approved labeling for losartan covers three indications: hypertension, diabetic nephropathy in patients with type 2 diabetes, and reduction of stroke risk in patients with hypertension and left ventricular hypertrophy (FDA label). All three indications use the same oral tablet formulation dosed once daily.

Branded Cozaar, manufactured by Merck, carries a list price near $80 per month. This number is largely academic. Fewer than 2% of losartan prescriptions filled in the United States use the brand-name product, according to IQVIA prescription tracking data. Idaho pharmacies almost universally dispense the generic unless a prescriber writes "dispense as written." Price variation between Idaho cities is minimal for generics but can be significant for the brand. Patients in Boise, Idaho Falls, Meridian, and Nampa report similar generic pricing, while rural pharmacies sometimes add a small dispensing premium of $2 to $5.

Idaho Medicaid and Losartan Coverage

Idaho Medicaid does not currently list losartan on its preferred drug list (PDL). This does not mean the drug is entirely inaccessible through Medicaid, but it does mean the path is less straightforward than it would be for a preferred ARB.

When a drug falls off the PDL, Idaho Medicaid typically requires prior authorization (PA) before covering it. The prescribing clinician must submit documentation showing medical necessity, which for an ARB usually means demonstrating that the patient either failed a preferred alternative or has a clinical reason (such as a specific side-effect profile or drug interaction) that makes losartan the better choice. Idaho's Medicaid PDL has historically preferred certain other ARBs, including valsartan, though formulary composition shifts annually based on supplemental rebate negotiations between the state and manufacturers (Idaho Medicaid pharmacy resources).

For patients enrolled in one of Idaho's Medicaid managed care plans, the formulary may differ from the fee-for-service PDL. Blue Cross of Idaho and Molina Healthcare, the two primary managed care organizations serving Idaho Medicaid enrollees, maintain their own drug lists. Patients should verify coverage directly with their plan before assuming losartan requires PA.

The practical impact of non-preferred status is often small. Because generic losartan costs approximately $10 per month at cash price, some patients and clinicians skip the PA process entirely and pay out of pocket. At that price point, the administrative burden of prior authorization can exceed the financial benefit of coverage.

Insurance Coverage Across Idaho Plans

Nearly every commercial health insurance plan sold in Idaho covers generic losartan. ARBs are a foundational drug class in cardiovascular medicine, and losartan's generic status places it on the lowest cost-sharing tiers of most formularies.

On Idaho's state health insurance exchange (Your Health Idaho), all qualified health plans must cover at least one drug in each pharmacological category under the ACA essential health benefits mandate. ARBs are included. Losartan typically sits on Tier 1 (preferred generic), which means copays range from $0 to $15 per month depending on the plan. Blue Cross of Idaho, SelectHealth, and Mountain Health CO-OP, the three major carriers on the exchange, all include generic losartan on their 2026 formularies.

Employer-sponsored plans follow a similar pattern. Large employers in Idaho's major industries (agriculture, technology in the Boise corridor, healthcare, and food processing) generally offer pharmacy benefits that place losartan at the lowest tier. Self-insured employer plans may vary, but losartan's rock-bottom acquisition cost makes it a standard formulary inclusion.

Medicare Part D plans in Idaho also cover losartan universally. Under the Inflation Reduction Act provisions that took full effect in 2025, Medicare beneficiaries now have a $2,000 annual out-of-pocket cap on prescription drugs (CMS Medicare drug coverage). For a medication costing $10 per month, this cap is unlikely to be relevant, but it provides additional cost certainty for patients taking multiple medications alongside losartan.

The LIFE trial (N=9,193), published in The Lancet in 2002, established losartan's superiority over atenolol for stroke prevention in hypertensive patients with left ventricular hypertrophy, with a 25% relative risk reduction in the primary composite endpoint (Dahlöf et al., Lancet 2002). This evidence base is one reason insurers consistently cover the drug without restrictions.

Telehealth Prescribing in Idaho

Idaho permits telehealth prescribing of losartan. A licensed clinician can evaluate a patient via video or audio visit, diagnose hypertension, and prescribe losartan without an in-person exam, provided the encounter meets Idaho Board of Medicine standards for establishing a patient-provider relationship.

Idaho's telehealth parity law (Idaho Code § 54-5707) requires commercial insurers to cover telehealth services at the same rate as in-person visits. This means a patient in rural Salmon, Idaho, has the same access to a losartan prescription as someone walking into a Boise clinic. The prescription can then be filled at any Idaho pharmacy or through a mail-order service.

Several national telehealth platforms operate in Idaho, including those that specialize in chronic disease management. Blood pressure monitoring kits shipped to the patient's home allow the prescribing clinician to review readings before initiating or adjusting losartan therapy. The American Heart Association recommends home blood pressure monitoring as a complement to office readings, noting that home measurements better predict cardiovascular outcomes than clinic-based readings alone (AHA home monitoring statement).

For patients in Idaho's more remote areas (the state ranks 7th in the nation by land area but 39th by population), telehealth eliminates a meaningful access barrier. Driving 90 minutes to a prescriber for a straightforward antihypertensive refill is a real obstacle in parts of central and eastern Idaho. Telehealth removes it.

Compounded Losartan in Idaho

Compounded losartan is available through licensed 503A compounding pharmacies operating in Idaho. A 503A pharmacy compounds medications pursuant to individual patient prescriptions, as opposed to 503B outsourcing facilities that produce larger batches without patient-specific prescriptions.

Compounding is most relevant for patients who cannot swallow standard tablets. Losartan is commercially available only as an oral tablet (25 mg, 50 mg, and 100 mg). For pediatric patients, patients with dysphagia, or those requiring a non-standard dose, a compounding pharmacy can prepare losartan as an oral suspension or in a different concentration. The FDA's prescribing information for losartan includes instructions for preparing an extemporaneous suspension from tablets, but many clinicians prefer a professionally compounded preparation for consistency.

Idaho's Board of Pharmacy regulates 503A compounding pharmacies under IDAPA 27.01.01. These pharmacies must comply with United States Pharmacopeia (USP) chapters 795 (nonsterile compounding) and 797 (sterile compounding, if applicable). Patients should confirm that any compounding pharmacy they use holds a current Idaho Board of Pharmacy license.

Cost for compounded losartan varies. Because the active ingredient is inexpensive and widely available in powder form, compounded preparations sometimes cost less than commercially manufactured tablets. Some Idaho compounding pharmacies offer compounded losartan suspensions for minimal cost when the patient also fills other compounded prescriptions. The actual price depends on the pharmacy, the formulation complexity, and whether insurance covers compounded medications (many plans do not).

Discount Programs and Savings Cards

Multiple discount pathways exist for patients seeking to reduce their losartan costs in Idaho below the already-low cash price.

Pharmacy discount programs. Walmart's $4 generic list, Costco's member pricing, and Fred Meyer's discount generics program all include losartan. These programs do not require insurance and are available to any patient with a valid prescription. The $4 price typically applies to a 30-day supply of losartan 25 mg or 50 mg; the 100 mg dose may be slightly higher at some locations.

Free discount cards. GoodRx, RxSaver, and similar platforms offer downloadable or printable discount cards that Idaho pharmacies accept. These cards negotiate pricing through pharmacy benefit managers and can bring losartan's cost to $4 to $8 at most chain pharmacies. The discount varies by location and fluctuates over time.

Manufacturer savings. Merck does not offer a branded Cozaar savings card for commercially insured patients in 2026, as the drug lost patent exclusivity in 2010. Generic manufacturers generally do not offer savings cards because the price is already at commodity levels. However, some generic manufacturers participate in patient assistance programs for uninsured individuals.

340B pricing. Patients who receive care at 340B-eligible entities (federally qualified health centers, certain hospital outpatient departments, and Ryan White clinics) may access losartan at substantially reduced prices. Idaho has 17 federally qualified health center organizations with multiple sites, many of which dispense 340B-priced medications through in-house or contract pharmacies. At 340B pricing, losartan may cost the dispensing entity less than $1 per month.

State pharmaceutical assistance. Idaho does not operate a state pharmaceutical assistance program (SPAP) for non-Medicare populations. However, the Idaho Department of Health and Welfare's Navigator program can help uninsured residents identify federal programs, manufacturer assistance, and community resources for medication costs.

Clinical Context: Why Losartan Is Prescribed

Losartan blocks the angiotensin II type 1 (AT1) receptor, reducing vasoconstriction, aldosterone secretion, and sympathetic nervous system activation. The net effect is lower blood pressure and reduced cardiac and renal stress. It was the first ARB approved by the FDA, receiving approval in 1995.

Three FDA-approved indications drive the majority of losartan prescriptions. Hypertension is the most common. The 2017 ACC/AHA blood pressure guideline lowered the diagnostic threshold for hypertension to 130/80 mmHg, increasing the number of American adults classified as hypertensive to nearly half the adult population (Whelton et al., JACC 2018). ARBs, including losartan, are recommended as first-line therapy alongside ACE inhibitors, calcium channel blockers, and thiazide diuretics.

Diabetic nephropathy is the second indication. The RENAAL trial (N=1,513) demonstrated that losartan 50 to 100 mg daily reduced the risk of doubling of serum creatinine by 25% and end-stage renal disease by 28% compared to placebo in patients with type 2 diabetes and nephropathy (Brenner et al., NEJM 2001). This renal protective effect operates partly independent of blood pressure reduction.

Stroke risk reduction is the third indication, supported by the LIFE trial. In that study, losartan-based therapy reduced the primary composite of cardiovascular death, stroke, and myocardial infarction by 13% compared to atenolol-based therapy (p=0.021), with the stroke reduction component driving most of the benefit (25% relative risk reduction, p=0.001) (Dahlöf et al., Lancet 2002).

Dr. Suzanne Oparil, past president of the American Heart Association, has noted: "ARBs like losartan offer a tolerability advantage over ACE inhibitors, particularly the absence of cough, which affects 5 to 20 percent of ACE inhibitor users." This tolerability profile makes losartan a common second-line choice when patients cannot tolerate an ACE inhibitor, and a reasonable first-line option in its own right.

How to Get the Lowest Price in Idaho

The practical algorithm for minimizing losartan cost in Idaho is short. First, confirm with your prescriber that generic losartan (not branded Cozaar) is appropriate. Second, check whether your insurance formulary covers losartan at Tier 1. If yes, fill through your plan and expect a copay between $0 and $15. If you are uninsured or your copay exceeds the cash price, use a pharmacy discount card (GoodRx or equivalent) and fill at Walmart, Costco, or a similar retailer offering $4 generic pricing.

For patients on Idaho Medicaid whose plan does not cover losartan without PA, discuss with your prescriber whether requesting prior authorization is worthwhile given the $10 monthly cash alternative. The time cost of the PA process may not justify the savings if the cash price is already within budget.

The Endocrine Society's 2020 clinical practice guideline on pharmacological management of hypertension recommends that clinicians consider out-of-pocket cost when selecting antihypertensive agents, noting that medication adherence drops significantly when monthly costs exceed $20 (Endocrine Society guideline). Losartan, at $4 to $10 per month in Idaho, sits well below that adherence threshold.

Dr. Paul Whelton, chair of the 2017 ACC/AHA hypertension guideline writing committee, stated: "Cost is a real barrier to blood pressure control in America. When a highly effective medication is available for a few dollars a month, clinicians should make patients aware of that option." In Idaho, losartan meets that standard.

Losartan Dosing and What to Expect

Standard initial dosing for hypertension is 50 mg once daily, with a maximum dose of 100 mg daily. Patients with intravascular volume depletion (such as those on diuretics) should start at 25 mg. Blood pressure reduction typically becomes apparent within one week, with maximal effect at three to six weeks (FDA losartan label).

For diabetic nephropathy, the target dose used in RENAAL was 100 mg daily. Clinicians often titrate from 50 mg to 100 mg over two to four weeks while monitoring serum potassium and creatinine. Potassium monitoring is especially important in patients with chronic kidney disease (eGFR <60 mL/min/1.73 m²), diabetes, or concurrent use of potassium-sparing diuretics.

Side effects are infrequent. The most common adverse reactions in clinical trials were dizziness (2.4% vs. 1.3% placebo), upper respiratory infection, and nasal congestion. Unlike ACE inhibitors, losartan does not cause cough in most patients. Angioedema is rare but possible, occurring at a lower rate than with ACE inhibitors. Losartan is contraindicated in pregnancy (category D in the second and third trimesters) due to risk of fetal renal damage and death.

Patients filling losartan at an Idaho pharmacy for the first time should expect the pharmacist to verify the dose, confirm no drug interactions with concurrent medications, and counsel on the importance of consistent daily use. Missing doses reduces blood pressure control proportionally to the number of missed days.